Ikonisys SA Announces the Appointment of Gabriel Plan as France Sales Director
01 Février 2022 - 6:00PM
Business Wire
A key position to enhance growth and
commercial expansion in Europe
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO)
(Paris:ALIKO), a company specializing in the early and
accurate detection of cancer with a unique fully-automated solution
for medical analysis laboratories, is very pleased to announce that
diagnostic industry expert Gabriel Plan joins as Ikonisys’ Sales
Director for the French market. Gabriel’s responsibilities will
encompass accelerating Ikoniscope20 sales in France and other
French speaking parts of Europe by acquiring new customers,
prominent KOLs (Key Opinion Leaders) and additional reference
labs.
Gabriel brings over ten years of sales and marketing experience
to Ikonisys, entirely spent in the molecular diagnostics sector.
Gabriel gained commercial expertise especially at MP Biochemicals,
a global supplier and manufacturer of life science, biochemicals
and diagnostic products. He started there as sales representative,
later moved to marketing, and then for several years was head of
sales of diagnostics for Western Europe. Gabriel has a master’s
degree in molecular diagnostics and business management from the
University of Paris-Sud XI.
“Gabriel is an important recruitment for Ikonisys as he brings
further commercial and technical knowledge of the field where we
operate” said Jurgen Schipper, Chief Commercial Officer of
Ikonisys. “As Ikonisys focuses across not only in the United
States but also in Europe, Gabriel’s knowledge of the French market
and his significant sales experience will accelerate Ikonisys’
growth in one of the most important worldwide markets for Ikonisys”
continued Jurgen Schipper.
“I am very honored to join Ikonisys and be able to participate
in the development and deployment of the company in Europe.
Ikonisys is particularly well positioned to support French
diagnostic laboratories in their process to expand their business
through unsurpassed level of automated detection and analysis of
rare tumor cells, and by subsequent optimization of their workflow”
stated Gabriel Plan, Sales Director, France.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare cells.
Ikonisys has received FDA clearance for several automated
diagnostic applications, which are also marketed in Europe under CE
certification. Through its breakthrough fluorescence microscopy
platform, the company continues to develop a stream of new tests,
including liquid biopsy tests based on Circulating Tumor Cells
(CTC).
For further information, please go to www.Ikonisys.com
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220201005868/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024